Marengo Therapeutics, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2015-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.marengotx.com
Clinical Trials
4
Active:2
Completed:0
Trial Phases
1 Phases
Phase 1:4
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials
Phase 1
4 (100.0%)A Study of Invikafusp Alfa (STAR0602), a Selective T Cell Receptor (TCR)-Targeting, Bifunctional Antibody-fusion Molecule, in Combination With Sacituzumab Govitecan in Participants With Advanced Solid Tumors
Phase 1
Recruiting
- Conditions
- Triple Negative Locally Advanced Non-resectable Breast CancerHR+, HER2-, Advanced Breast Cancer
- Interventions
- Drug: Sacituzumab Govitecan (SG)
- First Posted Date
- 2025-02-14
- Last Posted Date
- 2025-04-09
- Lead Sponsor
- Marengo Therapeutics, Inc.
- Target Recruit Count
- 50
- Registration Number
- NCT06827613
- Locations
- 🇺🇸
Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
🇨🇦Princess Margaret Cancer Centre, Toronto, Ontario, Canada
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
Phase 1
Recruiting
- Conditions
- Genital Neoplasm, FemaleUrogenital NeoplasmsLung NeoplasmNeoplasms by SitePapillomavirus InfectionEpstein-Barr Virus InfectionsAdvanced Solid TumorsCarcinomaNeoplasmsVulvar Neoplasms
- Interventions
- First Posted Date
- 2022-10-24
- Last Posted Date
- 2025-07-09
- Lead Sponsor
- Marengo Therapeutics, Inc.
- Target Recruit Count
- 365
- Registration Number
- NCT05592626
- Locations
- 🇺🇸
Loma Linda University Cancer Center, Loma Linda, California, United States
🇺🇸UC Davis Comprehensive Cancer Center, Sacramento, California, United States
🇺🇸Sarah Cannon Research Institute at HealthONE, Denver, Colorado, United States
News
No news found